Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
The Netherlands Cancer Institute
M.D. Anderson Cancer Center
University of Chicago
AstraZeneca
Neonc Technologies, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
H. Lee Moffitt Cancer Center and Research Institute
PrECOG, LLC.
National Cancer Institute (NCI)
Washington University School of Medicine
Big Ten Cancer Research Consortium
Big Ten Cancer Research Consortium
Dana-Farber Cancer Institute
University Health Network, Toronto
Bristol-Myers Squibb
Brown University
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Intergroupe Francophone de Cancerologie Thoracique
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Vivace Therapeutics, Inc
ImmunityBio, Inc.
Duke University
Memorial Sloan Kettering Cancer Center
7 Hills Pharma, LLC
Vyriad, Inc.
University of Alabama at Birmingham
TCR2 Therapeutics
Incyte Corporation
Yale University
Iovance Biotherapeutics, Inc.
GlaxoSmithKline
The First Affiliated Hospital of Guangzhou Medical University
Duke University
University of Utah
Fundación GECP
M.D. Anderson Cancer Center
Intensity Therapeutics, Inc.
Agenus Inc.
H. Lee Moffitt Cancer Center and Research Institute
Anaveon AG
Vanderbilt-Ingram Cancer Center
Second Affiliated Hospital of Guangzhou Medical University
Xencor, Inc.